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T
here is no doubt that the global 
burden of schizophrenia, a 
chronic serious mental illness, 
is massive. It is therefore essential that 
any intervention is appropriate, cost-
effective, and efﬁ  cacious. 
To reduce the burden, a clear 
epidemiologically based dataset is 
required. The ﬁ  rst step in such a 
venture is provided by Saha et al. in 
their systematic review of prevalence 
data on schizophrenia across cultures, 
published in this month’s PLoS Medicine 
[1]. Using a number of strategies these 
authors have distilled the ﬁ  ndings from 
just under 200 studies from 46 nations. 
Deﬁ  ning the Prevalence 
of the Disease
The prevalence rates of schizophrenia 
depend upon a whole range of 
factors, such as the availability of and 
response to treatment. The prevalence 
of schizophrenia, as with other 
mental disorders, can be calculated 
from a number of sources—from 
case registers to ﬁ  eld surveys. The 
latter lend themselves more readily 
to estimation of period prevalence 
(see Glossary) than point prevalence, 
while case register data can provide 
point prevalence more readily. The 
denominator can be the whole 
population or only a small deﬁ  ned 
population.
Saha et al. quite rightly differentiate 
between traditional prevalence, or 
“core”, studies (these generate an 
estimate based on the population 
residing within a deﬁ  ned catchment 
area), and studies in speciﬁ  c sub-groups 
(which they divide into migrant studies 
and studies in other special groups). 
Using sequential ﬁ  lters they were able 
to isolate discrete data from multiple 
studies, and they used other strategies 
to ensure that the largest groups were 
counted.
The authors had hypothesised that 
prevalence estimates would differ 
between lifetime, period, and point 
prevalence and that lifetime prevalence 
would be higher than lifetime 
estimates (estimates are calculated 
as a proportion by dividing the total 
number of individuals who manifest a 
disorder [the numerator] by the total 
population at risk including those 
with the disorder [the denominator]). 
They also predicted that the estimates 
would be higher for males, those 
from urban areas, and migrants. Case 
ascertainment methods and sample 
selection do inﬂ  uence prevalence rates, 
so Saha et al. chose studies that used 
comprehensive case ascertainment 
methods.
Findings of the Study
Of the 132 core studies, 21 studies 
reported point prevalence, 34 
reported period prevalence, and 24 
reported lifetime prevalence. The 
median prevalence of schizophrenia 
was 4.6/1,000 for point prevalence, 
3.3/1,000 for period prevalence, 4.0 for 
lifetime prevalence, and 7.2 for lifetime 
morbid risk.
There were no signiﬁ  cant differences 
between males and females, nor 
between urban, rural, and mixed 
sites, although migrants and 
homeless people had higher rates of 
schizophrenia and, not surprisingly, 
developing countries had lower 
prevalence rates (the lower prevalence 
of schizophrenia in developing 
countries has been previously 
documented). It is well known from 
other studies that migrants have higher 
than expected rates of schizophrenia 
[2–8], although deﬁ  nitions of migrants 
in these studies have been variable and 
the studies have suffered from a series 
of other methodological problems.
Implications of the Study
Several important ﬁ  ndings emerge 
from Saha and colleagues’ analysis. For 
clinicians, the analysis indicates clearly 
that lifetime prevalence is 4.0/1,000 and 
not 1%, as reported in the Diagnostic 
and Statistic Manual of Mental Disorders, 
fourth edition [9], and other textbooks. 
The study also challenges the 
widely held view that schizophrenia 
is much more common in men. Saha 
et al.’s ﬁ  nding that schizophrenia was 
just as common in women has clear 
implications for developing services, 
since it means that not only must 
we develop and provide culturally 
appropriate services but also services 
that are gender sensitive (as the 
number of cases in women are higher 
than expected, gender becomes a more 
important factor). Furthermore, if the 
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prodrome of the illness is long, this 
will affect the number of new cases 
appearing in the population, and 
longer delays in treatment will also 
affect the rates.
An important question for the 
researchers is whether cases counted as 
positive included patients with positive 
and/or negative symptoms, those who 
may have had underlying cognitive 
deﬁ  cits, and those whose illness was 
treatment resistant. 
Detailed economic measures must be 
included in analyses of the prevalence 
of schizophrenia to determine whether 
countries are developed or developing. 
Saha et al. themselves acknowledge 
that they have used a single measure of 
World Bank deﬁ  nitions relying on per 
capita income (whereas in any country 
there will be marked geographical 
variation in social and economic 
classes) for assessing a complex and 
multi-dimensional concept, which 
is a weak point of their systematic 
review. The impact of urbanisation 
must be studied especially, as in many 
developing or low-income countries 
the migration into urban areas adds a 
tremendous amount of variation that 
must be taken into account in future 
ecological studies. 
The authors acknowledge that their 
systematic review may have missed 
some studies, and they encourage 
readers who know about missing 
studies to contact them.
Schizophrenia across Cultures
Studies have shown that the outcome 
of schizophrenia is better in developing 
countries [10–12], and therefore 
the point prevalence in these 
countries should be lower. Despite 
this clear difference in the course of 
schizophrenia in different cultures, 
cross-cultural research in psychiatry 
focuses on similarities rather than 
differences. Kleinman suggests that 
there is a very strong bias towards 
discovering universals in mental 
disorder [13]. Both the International 
Pilot Study of Schizophrenia [10] and 
the Determinants of Outcome of Severe 
Mental Disorders study [12] used a 
template of symptoms of psychosis 
across cultures to identify groups of 
patients who seemed similar, but these 
studies left out all those patients who 
failed to ﬁ  t the template. It is these 
excluded patients that Kleinman 
suggests are of greater interest from 
a cultural perspective simply because 
they are the ones who would reveal the 
greatest amount of cultural diversity. 
In the  International Pilot Study 
of Schizophrenia  [10] and  the 
Determinants of Outcome of Severe 
Mental Disorders study [12], catatonia 
(a form of schizophrenia characterized 
by a tendency to remain in a ﬁ  xed 
stuporous state for long periods) 
was diagnosed in 10% of cases in 
developing countries compared with 
less than 1% in developed countries. 
Hebephrenia (a form of schizophrenia 
characterized by severe disintegration 
of personality) was present in 13% 
of cases in developed countries and 
4% in developing countries. These 
differences in the disease in developed 
versus developing countries indicate 
that there is more to the prevalence 
of schizophrenia than simple 
epidemiological data. Better prognosis 
in developing countries may indicate 
different sets of aetiological and 
perpetuating factors [14]. 
Cohen [15] argued that although 
the case-ﬁ  nding method in both these 
studies was accurate, the vast majority 
of cases were identiﬁ  ed in Western-type 
facilities, and therefore the numbers 
of true cases of schizophrenia may be 
an underestimate. He also pointed 
out that in developing countries the 
proportion of cases with acute onset 
schizophrenia was twice as high as in 
developed countries. Such variations 
may indicate a real difference in 
the cross-cultural manifestations of 
schizophrenia—hospital-based data 
collection reﬂ  ects cultural processes 
that have little to do with the true 
prevalence and incidence rates of 
schizophrenia.  
While prevalence studies can help 
contribute to an understanding 
of the aetiology of schizophrenia, 
psychodynamic issues—such as cultural 
identity and attachment—must also 
be studied, especially among migrant 
groups, as cultural congruity and ethnic 
density may inﬂ  uence the presentation 
of suffering individuals to psychiatric 
services [16,17].  
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Glossary
Point prevalence: The proportion of 
individuals who manifest a disorder at a 
given point in time.
Period prevalence: The proportion of 
individuals who manifest a disorder over 
a speciﬁ  c period of time (e.g., over one 
year).
Lifetime prevalence: The proportion of 
individuals in the population who have 
ever manifested a disorder, who are alive 
on a given day.
Lifetime morbid risk: The probability 
of a person developing the disorder 
during a speciﬁ  ed period of their life or 
up to a speciﬁ  ed age (lifetime morbid risk 
differs from lifetime prevalence in that it 
attempts to include the entire lifetime of 
a birth cohort both past and future, and 
includes those deceased at the time of 
the survey).